Clinical Laserthermia Systems
Lund
About Clinical Laserthermia Systems
Clinical Laserthermia Systems (CLS) develops and markets the TRANBERG®|Thermal Therapy System, as well as disposable materials and methods, for heat-induced immunotherapy enabling safe and gentle treatment of cancerous tumors. The products are marketed for image-guided laser ablation and for CLS’ own immunostimulating therapy, imILT®. The company is headquartered in Lund, Sweden, with subsidiaries in Berlin, Germany and in Boston, USA. CLS is listed on Nasdaq First North under the stock symbol CLS B.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $6.6M
- Funding stage: IPO
- Last round: Post-IPO Equity (Sep 2025)
- Ticker: fra:LS60
- Website: clinicallaser.se
- Phone: 046-15 21 00
Industries & Categories
Biotechnology, Laser, Medical Device, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/clinical-laserthermia-systems-72469 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.